STOCK TITAN

Avalon GloboCare Corp. - ALBT STOCK NEWS

Welcome to our dedicated page for Avalon GloboCare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon GloboCare stock.

Avalon GloboCare Corp. (NASDAQ: ALBT) is a pioneering biotech company specializing in precision diagnostics, clinical laboratory services, and transformative biotechnology. The company operates through two primary segments: the real property operating segment, which drives its revenue, and the medical-related consulting services segment. As an innovative healthcare service provider, Avalon focuses on key diagnostic and therapeutic areas such as early detection of oral, ovarian, and kidney cancers, as well as skin regeneration and treatments for degenerative disorders.

Headquartered in Freehold, NJ, Avalon is committed to advancing high-impact biotechnology and clinical applications. Recently, the company launched Veritas Laboratory in Scottsdale, Arizona, a CLIA-certified and COLA-accredited facility offering comprehensive drug, genetic, urinary, and COVID-19 PCR testing. Moreover, Avalon continuously expands its testing footprint nationwide, leveraging the expertise of former Congressman Barry M. Goldwater Jr. to enhance insurance coverage and laboratory reach.

The company has introduced groundbreaking innovations such as the proprietary TB detection method and the KetoAir™ breathalyzer. The TB test, developed by Laboratory Services MSO, LLC (LSM), uses PCR technology for rapid and accurate tuberculosis detection from sputum samples. The KetoAir™ breathalyzer, a partnership with Qi Diagnostics, offers AI-driven nutritional insights for ketogenic dietary management.

Avalon’s strategic acquisitions underscore its growth trajectory. The acquisition of Merlin Medical Supply (MMS) and Leading Edge Innovations enhances its portfolio with durable medical equipment and the GeeWhiz External Condom Catheter, bolstering its presence in the medical supply market.

Further strengthening its intellectual property, Avalon recently secured a patent for QTY-Code modified cytokine and chemokine protein receptors, expanding the therapeutic targets for diseases like cancer. The company continues to innovate with upcoming studies on the DKAir™ breathalyzer for early detection of diabetic ketoacidosis.

For detailed information about Avalon GloboCare’s projects, recent developments, and strategic initiatives, visit their website and follow them on Twitter at @avalongc_avco.

Rhea-AI Summary
Avalon GloboCare Corp. announces the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference. The cutting-edge breathalyzer features AI-enabled software, nano-sensor-based technology, and FDA registration. The KetoAir™ breathalyzer allows users to assess ketosis status, record diet and exercise details, and receive personalized nutritional and exercise recommendations. The product aims to provide a holistic solution to monitor and optimize ketosis state and body fat burning rate, setting a new standard in the market. Consumers can purchase the KetoAir™ breathalyzer exclusively at KetoAir.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.54%
Tags
none
-
Rhea-AI Summary
Avalon GloboCare Corp. extends its exclusive distribution agreement with Qi Diagnostics to distribute the innovative KetoAir™ breathalyzer device for ketogenic health management. The device, equipped with AI-enabled software and nanosensor-based technology, offers personalized nutritional and exercise recommendations. Avalon aims to target the diabetes reversal and obesity management markets, with a soft launch planned for 2024 and a full-scale launch in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
AI
-
Rhea-AI Summary
Avalon GloboCare Corp. (ALBT) partners with ChtrBx to develop a marketing launch plan for KetoAir™, a companion diagnostic and monitoring device for ketogenic dietary management. The pocket-sized breathalyzer provides accurate and instant results, and the company plans to soft launch in 2024 followed by a hard launch in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.13%
Tags
none
Rhea-AI Summary
Avalon GloboCare Corp. partners with Qi Diagnostics to co-develop international multi-center clinical studies for DKAir™ breathalyzer device for early detection of diabetic ketoacidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.67%
Tags
partnership clinical trial
-
Rhea-AI Summary
Avalon GloboCare Corp. launches the KetoAir™ mobile application in the Apple App store and Google Play store. The app is a companion diagnostic and monitoring device for ketogenic dietary management. The KetoAir™ breathalyzer device provides accurate and instant results, helping users monitor their ketone levels and optimize their ketosis state. The app also includes an AI nutritionist that offers personalized recommendations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
Rhea-AI Summary
Avalon GloboCare Corp. announces acquisition of Merlin Medical Supply and Leading Edge Innovations by Laboratory Services MSO, LLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
Rhea-AI Summary
Avalon GloboCare receives patent for QTY-Code modified cytokine and chemokine protein receptor molecules
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27%
Tags
none
-
Rhea-AI Summary
Avalon GloboCare Corp. announces new proprietary testing method for Tuberculosis diagnosis, expected to generate revenue in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.57%
Tags
none
-
Rhea-AI Summary
Avalon GloboCare Corp. opens new lab in Arizona, engages former Congressman Barry M. Goldwater Jr. to expand insurance coverage and grow lab footprint
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Avalon GloboCare Corp. (NASDAQ: ALBT) announced that Laboratory Services MSO, (LSM), in which Avalon owns a 40% interest, has acquired DE Laboratory (DE Labs) in Houston, Texas. This acquisition expands LSM's presence in Texas and offers significant growth potential. DE Labs is a CLIA-certified and COLA-accredited laboratory that performs about 1,500 lab tests per month, focusing on toxicology and wellness testing.

LSM will operate DE Labs as a fully owned subsidiary and has invested capital for geographical expansion into surrounding counties. The acquisition aligns with Avalon's strategy to expand LSM through acquisitions and strategic relationships in the fragmented laboratory testing market. Avalon aims to target laboratories with exceptional performance, positive revenue track records, and niche-market advantages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags

FAQ

What is the current stock price of Avalon GloboCare (ALBT)?

The current stock price of Avalon GloboCare (ALBT) is $2.78 as of November 20, 2024.

What is the market cap of Avalon GloboCare (ALBT)?

The market cap of Avalon GloboCare (ALBT) is approximately 2.9M.

What does Avalon GloboCare Corp. do?

Avalon GloboCare Corp. specializes in precision diagnostics, clinical laboratory services, and transformative biotechnology, focusing on areas like cancer detection and regenerative therapies.

What are the core segments of Avalon GloboCare's business?

Avalon operates through two primary segments: real property operating segment and medical-related consulting services segment.

What recent acquisitions has Avalon GloboCare made?

Avalon acquired Merlin Medical Supply, a provider of medical equipment, and Leading Edge Innovations, the owner of the GeeWhiz External Condom Catheter.

What is the KetoAir™ breathalyzer?

KetoAir™ is a breathalyzer device integrated with AI-enabled software for ketogenic dietary management, providing personalized nutritional recommendations.

What innovations has Avalon introduced in TB testing?

Avalon, through LSM, developed a proprietary PCR-based TB test that provides rapid and accurate detection from sputum samples.

Who is Barry M. Goldwater Jr. and how is he related to Avalon?

Barry M. Goldwater Jr., a former Congressman, has been engaged by Avalon to expand insurance coverage and grow their laboratory footprint in Arizona.

What is Avalon’s QTY-Code modified protein receptor patent?

The patent covers methods for making water-insoluble proteins soluble, expanding therapeutic targets for diseases like COVID-19 and cancers.

What is the DKAir™ breathalyzer?

DKAir™ is a handheld device developed by Qi Diagnostics and Avalon to detect diabetic ketoacidosis from breath acetone levels.

How is Avalon addressing the medical supply market?

Avalon acquired Merlin Medical Supply, a company with established payer relationships, enhancing its presence in the medical supply market.

How can I stay updated on Avalon GloboCare's developments?

For the latest updates, visit Avalon's website at www.avalon-globocare.com and follow their Twitter handle @avalongc_avco.

Avalon GloboCare Corp.

Nasdaq:ALBT

ALBT Rankings

ALBT Stock Data

2.89M
655.57k
37.47%
1.16%
10.14%
Real Estate Services
Biological Products, (no Disgnostic Substances)
Link
United States of America
FREEHOLD